Related Experiment Videos
[Modified endothelial cells in graft vasculopathy]
1Klinik für Thorax-, Herz- und Gefässchirurgie Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Laue@thg.mh-hannover.de
Zeitschrift Fur Kardiologie
|February 6, 2002
Summary
Modifying endothelial cells ex vivo offers a promising strategy to prevent graft vasculopathy in coronary artery bypass grafting and transplanted hearts, potentially reducing re-do operations and improving long-term outcomes.
Area of Science:
- Vascular Biology and Regenerative Medicine
- Cardiovascular Surgery
- Immunology
Context:
- Venous bypass graft occlusion is a primary cause of re-do coronary revascularization surgery.
- Coronary artery disease significantly limits the long-term success of cardiac transplantation.
- Endothelial dysfunction, driven by mechanical injury and pressure, leads to intimal hyperplasia and graft failure.
Purpose:
- To explore ex vivo modification of endothelial cells as a therapeutic approach for graft vasculopathy.
- To investigate the use of acellularized xenogenic matrices for vascular graft development.
- To assess gene therapy strategies for enhancing endothelial cell function in grafts.
Summary:
- Seeding endothelial cells onto artificial or bioartificial matrices is feasible.
- Recellularizing acellularized xenogenic matrices with autologous cells offers a potential solution for durable vascular and valvular grafts.
- Gene modification of endothelial cells, e.g., nitric oxide overexpression or matrix metalloproteinase inhibition, presents a novel therapeutic avenue.
Impact:
- Potential to reduce re-do operations in coronary revascularization.
- Improved long-term survival and function of transplanted hearts.
- Development of more durable vascular and valvular grafts for clinical use.
- Promising preclinical results in large animal studies suggest imminent clinical trials.